SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
Year: 2017
Type: article
Abstract: Some cancers evade targeted therapies through a mechanism known as lineage plasticity, whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no longer depends on the drug target. We use in vitro and in vivo human prostate cancer models to show that these tumors can develop resistance to the antiandrogen drug enzalutamide by a phenotypic shift from androgen receptor (AR)-dependent luminal epithelial cells to AR-independent basal-like cells. This lineage plasticity is enabled by the loss of TP53 and RB1 function, is mediated by increased expression of the reprogramming transcription factor SOX2, and can be reversed by restoring TP53 and RB1 function or by inhibiting SOX2 expression. Thus, mutations in tumor suppressor genes can create a state of increased cellular plasticity that, when challenged with antiandrogen therapy, promotes resistance through lineage switching.
Source: Science
Authors: Ping Mu, Zeda Zhang, Matteo Benelli, Wouter R. Karthaus, Elizabeth Hoover, Chi-Chao Chen, John Wongvipat, Sheng-Yu Ku, Dong Gao, Zhen Cao, Neel Shah, Elizabeth J. Adams, Wassim Abida, Philip A. Watson, Davide Prandi, Chun-Hao Huang, Elisa de Stanchina, Scott W. Lowe, Leigh Ellis, Himisha Beltran, Mark A. Rubin, David W. Goodrich, Francesca Demichelis, Charles L. Sawyers
Institutions: Memorial Sloan Kettering Cancer Center, Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, University of Trento, Cornell University, Weill Cornell Medicine, Roswell Park Comprehensive Cancer Center, Howard Hughes Medical Institute, NewYork–Presbyterian Hospital, Weill Cornell Medical Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Funders: American Association for Cancer Research, Prostate Cancer Foundation, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Stand Up To Cancer, National Cancer Institute, National Institute on Deafness and Other Communication Disorders, Congressionally Directed Medical Research Programs, DOD Prostate Cancer Research Program
Awards: Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer, Translational Research in Oncology Training Program, G2051006376, (PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes, Molecular Signatures of Lethal and Indolent Prostate Cancer, Drug Development and Cancer Treatments, MSKCC Pilot Center for Precision Disease Modeling, G8262573946, Understanding Resistance to Next Generation Antiandrogens, Targeting Transcription and Splicing in Cancer, Cancer Center Support Grant, Neural Prediction to Enhance Language Outcomes in Children with Cochlear Implant, Roswell Park Cancer Center Support Grant, SPORE in Prostate Cancer, Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence
OpenAlex ID: W2567986926
